Topics

Glioblastoma | Treatment | Immunotherapy | Vaccines

Home > Publications > Topics > Glioblastoma > Treatment > Immunotherapy > Vaccines

*Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G.
Glioblastoma vaccines: past, present, and opportunities.
EBioMedicine. 2024 Jan 5;100:104963. doi: 10.1016/j.ebiom.2023.104963. PMID: 38183840. Review. ˍ

Galanis E, Dooley KE, Keith Anderson S, Kurokawa CB, Carrero XW, Uhm JH, Federspiel MJ, Leontovich AA, Aderca I, Viker KB, Hammack JE, Marks RS, Robinson SI, Johnson DR, Kaufmann TJ, Buckner JC, Lachance DH, Burns TC, Giannini C, Raghunathan A, Iankov ID, Parney IF.
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.
Nat Commun. 2024 Jan 12;15(1):493. doi: 10.1038/s41467-023-43076-7. PMID: 38216554. Interventional study. ˍ

Squalli Houssaini A, Lamrabet S, Nshizirungu JP, Senhaji N, Sekal M, Karkouri M, Bennis S.
Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.
Vaccines (Basel). 2024 Jun 12;12(6):655. doi: 10.3390/vaccines12060655. PMID: 38932383. Review. ˍ

Dillman RO, Bota DA.
Next-generation vaccines are showing promise against glioblastoma.
Oncotarget. 2024 Aug 5;15:543-548. doi: 10.18632/oncotarget.28636. PMID: 39102214. Editorial. ˍ

Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O, Rabsteyn A, Harter J, Schulze M, Okech T, Golf A, Kyzirakos-Feger C, Kayser S, Pieper N, Feldhahn M, Wünsche J, Seitz C, Hadaschik D, Garbe C, Hauser TK, la Fougère C, Biskup D, Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal DT, Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S, Li WW, Li VW, Williams M, Miller AM, Kesari S, Castro M, Desjardins A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM, Sipos B, Geletneky K, Zender L, Glas M, Reardon DA, Biskup S.
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
Nat Commun. 2024 Aug 11;15(1):6870. doi: 10.1038/s41467-024-51315-8. PMID: 39127809. Observational study. ˍ

Strika Z, Petković K, Likić R.
Effectiveness and Safety of mRNA Vaccines in the Therapy of Glioblastoma.
J Pers Med. 2024 Sep 19;14(9):993. doi: 10.3390/jpm14090993. PMID: 39338247. Perspective. ˍ

Karimi-Sani I, Molavi Z, Naderi S, Mirmajidi SH, Zare I, Naeimzadeh Y, Mansouri A, Tajbakhsh A, Savardashtaki A, Sahebkar A.
Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials.
J Nanobiotechnology. 2024 Oct 4;22(1):601. doi: 10.1186/s12951-024-02882-x. PMID: 39367418. Review. ˍ

Tapescu I, Madsen PJ, Lowenstein PR, Castro MG, Bagley SJ, Fan Y, Brem S.
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.
Front Oncol. 2024 Sep 27;14:1454370. doi: 10.3389/fonc.2024.1454370. PMID: 39399167. Review. ˍ

Tabatabai G, Platten M, Preusser M, Weller M, Wick W, van den Bent M.
Treatment of glioblastoma patients with personalized vaccines outside clinical trials: Lessons ignored?
Neuro Oncol. 2024 Nov 19:noae225. doi: 10.1093/neuonc/noae225. PMID: 39561243. Comment. ˍ
REFERS TO:
Latzer P, Zelba H, Battke F, Reinhardt A, Shao B, Bartsch O, Rabsteyn A, Harter J, Schulze M, Okech T, Golf A, Kyzirakos-Feger C, Kayser S, Pieper N, Feldhahn M, Wünsche J, Seitz C, Hadaschik D, Garbe C, Hauser TK, la Fougère C, Biskup D, Brooke D, Parker D, Martens UM, Illerhaus G, Blumenthal DT, Merrell R, Lorenzo LS, Hidvégi M, de Robles P, Kebir S, Li WW, Li VW, Williams M, Miller AM, Kesari S, Castro M, Desjardins A, Ashley DM, Friedman HS, Wen PY, Neil EC, Iwamoto FM, Sipos B, Geletneky K, Zender L, Glas M, Reardon DA, Biskup S.
A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
Nat Commun. 2024 Aug 11;15(1):6870. doi: 10.1038/s41467-024-51315-8. PMID: 39127809. Observational study. ˍ

Muragaki Y, Ishikawa E, Tamura M, Kawamata T, Gosho M, Hashimoto K, Komori T, Yokoo H, Matsutani M, Maebayashi K, Tanaka T, Yamaguchi S, Kanamori M, Yamamoto T, Hanihara M, Arakawa Y, Sasayama T, Abe T, Nakamura H, Mukasa A, Uzuka T, Nakajo K, Ohno T.
A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol.
Jpn J Clin Oncol. 2025 May 16:hyaf078. doi: 10.1093/jjco/hyaf078. PMID: 40377260. Interventional study protocol˰ ˍ

Elliott WJ, Gurramkonda N, Guda MR, Tsung AJ, Velpula KK.
Survivin Interference and SurVaxM as an Adjunct Therapy for Glioblastoma Multiforme.
Cells. 2025 May 21;14(10):755. doi: 10.3390/cells14100755. PMID: 40422257. Review. ˍ

Salahlou R, Farajnia S, Alizadeh E, Dastmalchi S.
Recent developments in peptide vaccines against Glioblastoma, a review and update.
Mol Brain. 2025 Jun 13;18(1):50. doi: 10.1186/s13041-025-01221-x. PMID: 40514725. Review. ˍ

Singh DD, Haque S, Singh AK, Yadav DK.
Advancing vaccine-based immunotherapy in glioblastoma treatment.
Neurooncol Adv. 2025 Jun 24;7(1):vdaf135. doi: 10.1093/noajnl/vdaf135. PMID: 40756669. Review. ˍ AI Overview

Jha R, Spanehl L, Chen JA, Gessler FA, Arnaout O, Valdes PA, Choi BD, Peruzzi PP, Bernstock JD, Chiocca EA.
Translational advancements in tumor vaccine therapies for glioblastomas.
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv72-iv83. doi: 10.1093/noajnl/vdaf051. PMID: 40933034. Review. ˍ

Bota DA, Piccioni DE, Duma CM, Kesari S, Carrillo JA, LaRocca RV, Aiken RD, Taylor TH, Abedi M, Robles RM, Godding K, Keirstead HS, Nistor GI, Dillman RO.
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival.
Hum Vaccin Immunother. 2025 Sep 12;21(1):2556591. doi: 10.1080/21645515.2025.2556591. PMID: 40938661. Interventional study. ˍ

Barati S, Ghoflchi S, Hosseinzadeh P, Pouramini S, Hosseini H, Jalili-Nik M.
Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine.
Cancer Med. 2025 Sep 15;14(18):e71187. doi: 10.1002/cam4.71187. PMID: 40948290. Review. ˍ

Hill CM, Wang AZ, Hsueh B, Ramirez R, Sherpa N, Costa M, Williams O, Li M, Dunn GP.
Immunologic specificity in glioblastoma: Antigen discovery and translational implications.
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv41-iv70. doi: 10.1093/noajnl/vdaf028. PMID: 40933038. Review. ˍ

Hu Y, Leng L, Li B, Qiao Q.
The advantages of NK cell vaccines in solid carcinoma clinical trials: conducted by various biology strategy and technology.
Front Med (Lausanne). 2025 Oct 17;12:1656570. doi: 10.3389/fmed.2025.1656570. PMID: 41179878. Review. ˍ